Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

21
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
21
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

126
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
126
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

24
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
24
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

41
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
41
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

404
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
404
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

146
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
146

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter on 'Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated MASH Cirrhosis for Fibrosis Regression and MASH Resolution'. Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Dietary Guidelines 2025-2030 For Americans Are Concerning For Liver Health.

The American journal of gastroenterology·2026
Same author

The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology Commission.

The lancet. Gastroenterology & hepatology·2026
Same author

PREVALENCE AND RISK FACTORS ASSOCIATED WITH MASLD AND ADVANCED FIBROSIS AMONG OVERWEIGHT INDIVIDUALS: IMPLICATIONS FOR SCREENING GUIDELINES.

The American journal of gastroenterology·2026
Same author

Klebsiella genus as driver of human disease: from infections to non-communicable disorders.

Nature reviews. Microbiology·2026
Same author

Letter: Beyond Feasibility-The Need for Longer Duration and Composite NIT Endpoints in Biopsy-Free MASH Trials: Authors' Reply.

Alimentary pharmacology & therapeutics·2026

Related Experiment Video

Updated: Sep 7, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.1K

Current therapies and new developments in NASH.

Jean-François Dufour1, Quentin M Anstee2, Elisabetta Bugianesi3

  • 1Centre des Maladies Digestives, Lausanne, Switzerland jf.dufour@svmed.ch.

Gut
|June 16, 2022
PubMed
Summary
This summary is machine-generated.

Non-alcoholic steatohepatitis (NASH) is a leading cause of advanced liver disease. This review covers recent progress in understanding NASH, diagnostic biomarkers, lifestyle interventions, and drug trials, focusing on clinical management challenges.

More Related Videos

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.1K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.1K

Related Experiment Videos

Last Updated: Sep 7, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.1K
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.1K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.1K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Non-alcoholic steatohepatitis (NASH) is increasingly recognized as a primary driver of advanced liver disease.
  • Recent advancements have improved the understanding of NASH pathophysiology.
  • The growing prevalence necessitates effective management strategies.

Purpose of the Study:

  • To review the current landscape of non-alcoholic steatohepatitis (NASH) management.
  • To highlight challenges faced by healthcare professionals in managing NASH patients.
  • To discuss recent progress in biomarkers, lifestyle interventions, and pharmacotherapy.

Main Methods:

  • Literature review of recent advancements in NASH research and clinical practice.
  • Synthesis of information on diagnostic biomarkers (circulating and imaging).
  • Overview of lifestyle modifications and emerging drug therapies in clinical trials.

Main Results:

  • Multiple non-invasive biomarkers for NASH diagnosis and staging have been evaluated.
  • Lifestyle modifications are recognized as crucial for NASH management.
  • Several pharmaceutical agents are under investigation in clinical trials for NASH treatment.

Conclusions:

  • Effective management of NASH requires a multifaceted approach.
  • Healthcare professionals face challenges in integrating new diagnostic tools and therapies.
  • Continued research and clinical trials are essential for advancing NASH patient care.